Developmental Research Program

发展研究计划

• 批准号: 10415971
• 负责人: ANIRBAN MAITRA
• 金额: $ 15.27万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-20 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10415971
• 关键词: Area; Award; Basic Science; Budgets; Cancer Center; Clinical; Clinical Investigator; Collaborations; Colorectal Cancer; Communities; Community Developments; Complement; Data; Development; Direct Costs; Discipline; Disease; Educational Activities; Environment; Evaluation; Financial Support; Funding; Future; Goals; Guidelines; Human; Incidence; Institution; Laboratories; Lead; Leadership; Letters; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of pancreas; Medical Oncology; Medical center; Minority Groups; Modeling; Monitor; National Cancer Institute; Nature; Pathology; Patients; Physicians; Pilot Projects; Plant Roots; Population Research; Principal Investigator; Process; Program Research Project Grants; Quality of life; Records; Research; Research Activity; Research Personnel; Research Project Grants; Resources; Rest; Route; Scientist; Selection Criteria; Specimen; Texas; Text; Translational Research; Translations; Underrepresented Minority; United States National Institutes of Health; Universities; Woman; Work; anticancer research; base; flexibility; gastrointestinal; high risk; improved; innovation; member; mid-career faculty; molecular pathology; mortality; patient population; professor; programs; recruit; sound; translational cancer research; translational study

DEVELOPMENTAL RESEARCH PROGRAM: Summary/Abstract The purpose of the Developmental Research Program (DRP) is to fund highly innovative translational studies in colorectal cancer (CRC) or pancreatic cancer (PDAC) that currently lack a human endpoint as mandated by the SPORE guidelines, but that could become full SPORE projects with requisite DRP support, or compete successfully for funding outside of the SPORE mechanism. The DRP provides a unique venue for making available critical financial support, as well as disease-specific intellectual and resource expertise, through a program that is rapidly responsive to new ideas or initiatives, including from investigators whose current work may not focus exclusively in CRC or PDAC research. This program is rooted in a spirit of collaboration espoused by the GI SPORE leadership, which has an extensive track record of bringing investigators from other disciplines into the field of CRC and/or PDAC research. The strength of the DRP rests in its ability to make available financial support needed to access all the critical expertise and resources within the entire GI SPORE, including the proposed Cores. This will allow us to develop innovative, investigator-initiated projects that have the potential to flourish into reliable and productive translational research projects along a path from basic and/or population research projects into research focused on human clinical specimens/patient populations. The DRP will be coled by principal investigators of the SPORE including Dr. Anirban Maitra, the Scientific Director of the Sheikh Ahmed Center for Pancreatic Cancer Research, and Professor in the Departments of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center (UTMDACC) and Dr. Scott Kopetz, Associate Professor and Deputy Chair for Translational Research in the Department of Gastrointestinal Medical Oncology. The DRP will incorporate not only UTMDACC, but also our collaborating partner institution Johns Hopkins University (JHU) and other centers of excellence within the Texas Medical Center, providing an unprecedented seedbed for promoting innovative translational research projects in PDAC and CRC. Preproposals in the form of one page letters of intent (LOI) will be solicited by the Program, and following review by the DRP leadership, applicants of the responsive pre-proposals will be invited to submit a full proposal for review. The DRP Directors will help investigators submitting proposals to formulate translational research aims and plans relevant to the overall themes of the GI SPORE, as many applicants may not have prior expertise in this type of research. The overarching goal will be to facilitate research activities that will enable proposing a feasible human endpoint for future iterations of the funded proposal. This process will therefore be a major educational activity that is further anticipated to stimulate translational research in CRC or PDAC and encourage the participation of both basic science researchers and clinical investigators in translational research.

发展研究计划：摘要/摘要 发展研究计划（DRP）的目的是为高度创新的翻译研究提供资金 结直肠癌（CRC）或胰腺癌（PDAC）目前缺乏人类终点 孢子指南，但这可能成为必要的DRP支持或竞争的完整孢子项目 成功地用于孢子机制之外的资金。 DRP提供了一个独特的场所 可用的关键财务支持以及特定疾病的智力和资源专业知识，通过 迅速响应新想法或倡议的计划，包括来自当前工作的调查人员 可能不专注于CRC或PDAC研究。该计划植根于共同的精神 GI Spore Leadership的领导才能带来广泛的记录，从而带来了其他学科的调查员 进入CRC和/或PDAC研究领域。 DRP的优势取决于其提供财务的能力 访问整个GI孢子中所有关键专业知识和资源所需的支持，包括 拟议的核心。这将使我们能够开发创新的调查员发动的项目，这些项目有可能 沿着基本和/或人口的一条路径蓬勃发展 研究项目的研究重点是人类临床标本/患者人群。 DRP将由孢子的主要研究人员领导，包括酋长的科学主任Anirban Maitra博士 艾哈迈德胰腺癌研究中心，病理学系教授 UT MD Anderson癌症中心（UTMDACC）和Scott Kopetz博士的转化分子病理学， 胃肠道医学系副教授兼转化研究副主席 肿瘤学。 DRP不仅将纳入UTMDACC，还包括我们的合作合作伙伴机构Johns 霍普金斯大学（JHU）和德克萨斯医学中心内其他卓越中心 前所未有的苗床，用于促进PDAC和CRC中的创新转化研究项目。该计划将以一页意向书（LOI）的形式提出的预先提议，并在审查之后 DRP领导层，响应式前培训的申请人将被邀请提交一份完整的审查建议。 DRP董事将帮助调查人员提交提案以制定转化研究目的和计划 与GI孢子的整体主题相关，因为许多申请人可能没有此类专业知识 研究。总体目标将是促进研究活动，以提出可行的人类 资助提案的未来迭代的终点。因此，这个过程将是一项主要的教育活动 这进一步预期会刺激CRC或PDAC中的转化研究，并鼓励参与 基础科学研究人员和转化研究中的临床研究者。